High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer

Breast Cancer Research and Treatment

Volumn 125, Issue 2, 2011, Pages 395-406

  Met, Özcan ^a   Balslev, Eva ^a   Flyger, Henrik ^a   Svane, Inge Marie ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Breast cancer; Dendritic cells; Immunotherapy; mRNA transfection; Tumor associated antigens

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 2; MESSENGER RNA; PROTEIN P53;

ARTICLE; BREAST CANCER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOREACTIVITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENES, P53; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-2; RNA, MESSENGER; T-LYMPHOCYTES; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78650992314     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0844-9     Document Type: Article

References (51)

1. GP Dunn AT Bruce H Ikeda LJ Old RD Schreiber 2002 Cancer immunoediting: from immunosurveillance to tumor escape Nat Immunol 3 991 998 1:CAS:528:DC%2BD38Xot1Chs70%3D 10.1038/ni1102-991 12407406 (Pubitemid 35363648)
2. P van der Bruggen Y Zhang P Chaux, et al. 2002 Tumor-specific shared antigenic peptides recognized by human T cells Immunol Rev 188 51 64 10.1034/j.1600-065X.2002.18806.x (Pubitemid 35398865)
3. PJ Tacken IJ de Vries R Torensma CG Figdor 2007 Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting Nat Rev Immunol 7 790 802 1:CAS:528:DC%2BD2sXhtVOrtbjL 10.1038/nri2173 17853902 (Pubitemid 47480309)
4. VF Van Tendeloo P Ponsaerts ZN Berneman 2007 mRNA-based gene transfer as a tool for gene and cell therapy Curr Opin Mol Ther 9 423 431 17932806
5. VF Van Tendeloo P Ponsaerts F Lardon, et al. 2001 Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells Blood 98 49 56 10.1182/blood.V98.1. 49 11418462
6. JH Kessler CJ Melief 2007 Identification of T-cell epitopes for cancer immunotherapy Leukemia 21 1859 1874 1:CAS:528:DC%2BD2sXptlSrsrc%3D 10.1038/sj.leu.2404787 17611570 (Pubitemid 47299958)
7. M Theobald J Biggs D Dittmer AJ Levine LA Sherman 1995 Targeting p53 as a general tumor antigen Proc Natl Acad Sci USA 92 11993 11997 1:CAS:528:DyaK28Xhtlyrtw%3D%3D 10.1073/pnas.92.26.11993 8618830 (Pubitemid 26013997)
8. AB DeLeo TL Whiteside 2008 Development of multi-epitope vaccines targeting wild-type sequence p53 peptides Expert Rev Vaccines 7 1031 1040 1:CAS:528:DC%2BD1cXhtVOiur%2FM 10.1586/14760584.7.7.1031 18767952
9. ML Disis KL Knutson K Schiffman K Rinn DG McNeel 2000 Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer Breast Cancer Res Treat 62 245 252 1:CAS:528:DC%2BD3cXnvV2qurs%3D 10.1023/A:1006438507898 11072789
10. D Nagorsen C Scheibenbogen G Schaller, et al. 2003 Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients Int J Cancer 105 221 225 1:CAS:528:DC%2BD3sXjt12mtrY%3D 10.1002/ijc.11052 12673683 (Pubitemid 36505325)
11. C Rentzsch S Kayser S Stumm, et al. 2003 Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells Clin Cancer Res 9 4376 4386 1:CAS:528:DC%2BD3sXotVShsb8%3D 14555509
12. O Met J Eriksen IM Svane 2008 Studies on mRNA electroporation of immature and mature dendritic cells: effects on their immunogenic potential Mol Biotechnol 40 151 160 1:CAS:528:DC%2BD1cXht1ais7jI 10.1007/s12033-008-9071-6 18543130
13. AE Pedersen M Thorn M Gad, et al. 2005 Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination Scand J Immunol 61 147 156 1:STN:280:DC%2BD2M%2Fls1yhsg%3D%3D 10.1111/j.0300-9475.2005.01531.x 15683451 (Pubitemid 40255358)
14. I Garcia-Tunon M Ricote A Ruiz, et al. 2006 Cell cycle control related proteins (p53, p21, and Rb) and transforming growth factor beta (TGFbeta) in benign and carcinomatous (in situ and infiltrating) human breast: implications in malignant transformations Cancer Invest 24 119 125 1:CAS:528: DC%2BD28XisVartr0%3D 10.1080/07357900500524314 16537179
15. M McCutcheon N Wehner A Wensky, et al. 1997 A sensitive ELISPOT assay to detect low-frequency human T lymphocytes J Immunol Methods 210 149 166 1:CAS:528:DyaK1cXht1Wntbc%3D 10.1016/S0022-1759(97)00182-8 9520298 (Pubitemid 28266559)
16. IM Svane AE Pedersen JS Johansen, et al. 2007 Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers Cancer Immunol Immunother 56 1485 1499 1:CAS:528:DC%2BD2sXntVOlsb4%3D 10.1007/s00262-007-0293-4 17285289 (Pubitemid 47024713)
17. V Goodell LG Salazar N Urban, et al. 2006 Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer J Clin Oncol 24 762 768 1:CAS:528:DC%2BD28XitVGisbg%3D 10.1200/JCO.2005.03.2813 16391298 (Pubitemid 46622043)
18. D Valmori C Scheibenbogen V Dutoit, et al. 2002 Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity Cancer Res 62 1743 1750 1:CAS:528:DC%2BD38XisVSitr4%3D 11912149
19. V Karanikas D Colau JF Baurain, et al. 2001 High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival Cancer Res 61 3718 3724 1:CAS:528:DC%2BD3MXjsFCgurs%3D 11325844
20. TK Hoffmann AD Donnenberg SD Finkelstein, et al. 2002 Frequencies of tetramer + T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer Cancer Res 62 3521 3529 1:CAS:528:DC%2BD38XkslWqtrY%3D 12067999
21. K Chikamatsu K Sakakura G Takahashi, et al. 2009 CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer Cancer Immunol Immunother 58 1441 1448 1:CAS:528: DC%2BD1MXnslent78%3D 10.1007/s00262-009-0661-3 19184003
22. SH van der Burg K de Cock AG Menon, et al. 2001 Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer Eur J Immunol 31 146 155 10.1002/1521- 4141(200101)31:1<146::AID-IMMU146>3.0.CO;2-T 11169448 (Pubitemid 32096006)
23. PA Sotiropoulou SA Perez V Voelter, et al. 2003 Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/neu oncoprotein in patients with epithelial tumors Cancer Immunol Immunother 52 771 779 1:CAS:528: DC%2BD3sXovVKntL8%3D 10.1007/s00262-003-0420-9 13680193 (Pubitemid 37491705)
24. JD Lewis BD Reilly RK Bright 2003 Tumor-associated antigens: from discovery to immunity Int Rev Immunol 22 81 112 1:CAS:528:DC%2BD3sXitVektbg%3D 10.1080/08830180305221 12962271 (Pubitemid 36758540)
25. S Gnjatic Z Cai M Viguier, et al. 1998 Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas J Immunol 160 328 333 1:CAS:528:DyaK1cXhtFWguw%3D%3D 9551988
26. MP Vierboom S Zwaveling GMJ Bos, et al. 2000 High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes Cancer Res 60 5508 5513 1:CAS:528:DC%2BD3cXns1eht74%3D 11034095
27. M Inokuma C dela Rosa C Schmitt, et al. 2007 Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature J Immunol 179 2627 2633 1:CAS:528:DC%2BD2sXosVyqtrs%3D 17675526
28. N Sommerfeldt F Schutz C Sohn, et al. 2006 The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients Cancer Res 66 8258 8265 1:CAS:528:DC%2BD28XotFWquro%3D 10.1158/0008-5472.CAN-05-4201 16912206 (Pubitemid 44299195)
29. H Nishikawa T Kato K Tanida, et al. 2003 CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses Proc Natl Acad Sci USA 100 10902 10906 1:CAS:528:DC%2BD3sXnslyntLk%3D 10.1073/pnas.1834479100 12947044 (Pubitemid 37140125)
30. K Okada K Komuta S Hashimoto, et al. 2000 Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis Clin Cancer Res 6 3560 3564 1:CAS:528:DC%2BD3cXntFCisLw%3D 10999744
31. JT Kurnick T Ramirez-Montagut LA Boyle, et al. 2001 A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter J Immunol 167 1204 1211 1:CAS:528:DC%2BD3MXls1Wktbw%3D 11466335
32. EY Nikitina JI Clark J Van Beynen, et al. 2001 Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients Clin Cancer Res 7 127 135 1:CAS:528:DC%2BD3MXht1Whtrs%3D 11205900
33. J Humrich L Jenne 2003 Viral vectors for dendritic cell-based immunotherapy Curr Top Microbiol Immunol 276 241 259 1:CAS:528: DC%2BD3sXlsFersL4%3D 12797451
34. M Reuschenbach DM von Knebel N Wentzensen 2009 A systematic review of humoral immune responses against tumor antigens Cancer Immunol Immunother 8 1535 1544 10.1007/s00262-009-0733-4
35. L Vujanovic E Ranieri A Gambotto, et al. 2006 IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro Cancer Gene Ther 13 798 805 1:CAS:528:DC%2BD28XmvFyqsLs%3D 10.1038/sj.cgt.7700964 16645618 (Pubitemid 44100493)
36. K Minkis DG Kavanagh G Alter, et al. 2008 Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells Cancer Res 68 9441 9450 1:CAS:528: DC%2BD1cXhtlOmt7jI 10.1158/0008-5472.CAN-08-0900 19010919
37. K Hung R Hayashi A Lafond-Walker, et al. 1998 The central role of CD4(+) T cells in the antitumor immune response J Exp Med 188 2357 2368 1:CAS:528:DyaK1MXhtFejtw%3D%3D 10.1084/jem.188.12.2357 9858522 (Pubitemid 29028508)
38. DM Pardoll SL Topalian 1998 The role of CD4+ T cell responses in antitumor immunity Curr Opin Immunol 10 588 594 1:CAS:528:DyaK1cXmvVOls7k%3D 10.1016/S0952-7915(98)80228-8 9794842 (Pubitemid 28479193)
39. E Gilboa J Vieweg 2004 Cancer immunotherapy with mRNA-transfected dendritic cells Immunol Rev 199 251 263 1:CAS:528:DC%2BD2cXltFygsb8%3D 10.1111/j.0105-2896.2004.00139.x 15233739 (Pubitemid 38744521)
40. MR Muller F Grunebach A Nencioni P Brossart 2003 Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes J Immunol 170 5892 5896 12794115
41. JA Kyte G Kvalheim S Aamdal S Saeboe-Larssen G Gaudernack 2005 Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination Cancer Gene Ther 12 579 591 1:CAS:528:DC%2BD2MXktFOisbk%3D 10.1038/sj.cgt.7700837 15818380 (Pubitemid 40686598)
42. F Nimmerjahn S Milosevic U Behrends, et al. 2003 Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy Eur J Immunol 33 1250 1259 1:CAS:528:DC%2BD3sXjvFyjsro%3D 10.1002/eji.200323730 12731050 (Pubitemid 36609143)
43. MF Kalady MW Onaitis KM Padilla, et al. 2002 Enhanced dendritic cell antigen presentation in RNA-based immunotherapy J Surg Res 105 17 24 1:CAS:528:DC%2BD38XksFOgurY%3D 10.1006/jsre.2002.6435 12069496 (Pubitemid 34713206)
44. SK Nair D Boczkowski M Morse, et al. 1998 Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA Nat Biotechnol 16 364 369 1:CAS:528:DyaK1cXisVSmtb8%3D 10.1038/nbt0498-364 9555728 (Pubitemid 28164657)
45. N Schaft J Dorrie P Thumann, et al. 2005 Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation J Immunol 174 3087 3097 1:CAS:528: DC%2BD2MXhsFeqt7k%3D 15728524
46. M Javorovic H Pohla B Frankenberger T Wolfel DJ Schendel 2005 RNA transfer by electroporation into mature dendritic cells leading to reactivation of effector-memory cytotoxic T lymphocytes: a quantitative analysis Mol Ther 12 734 743 1:CAS:528:DC%2BD2MXhtVWgsbvK 10.1016/j.ymthe.2005.03.034 15921959 (Pubitemid 41350155)
47. RF Wang HY Wang 2002 Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells Nat Biotechnol 20 149 154 1:CAS:528:DC%2BD38Xht1eqsLc%3D 10.1038/nbt0202-149 11821860 (Pubitemid 34158030)
48. Y He J Zhang Z Mi P Robbins LD Falo Jr 2005 Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity J Immunol 174 3808 3817 1:CAS:528: DC%2BD2MXitVehtbw%3D 15749922
49. B Ludewig K McCoy M Pericin, et al. 2001 Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells J Immunol 166 3678 3687 1:CAS:528:DC%2BD3MXitVGntLk%3D 11238607
50. MF Bachmann RR Beerli P Agnellini, et al. 2006 Long-lived memory CD8+ T cells are programmed by prolonged antigen exposure and low levels of cellular activation Eur J Immunol 36 842 854 1:CAS:528:DC%2BD28XktVKkt7o%3D 10.1002/eji.200535730 16552716
51. DH Busch KM Kerksiek EG Pamer 2000 Differing roles of inflammation and antigen in T cell proliferation and memory generation J Immunol 164 4063 4070 1:CAS:528:DC%2BD3cXis1Wlu70%3D 10754299